drugset
drugset / Trial / NCT05526430

Study of Harmine in Healthy Subjects

NCT05526430 ↗

Phase 1 Completed 27 enrolled James Murrough National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSequentialOpen-labelTreatment

Summary

The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.

Timeline

Start
2022-09-13
Primary completion
2023-06-23
Completion
2023-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Harmine Small molecule 100 mg Oral
Subject Harmine Small molecule 200 mg Oral
Subject Harmine Small molecule 300 mg Oral
Subject Harmine Small molecule 500 mg Oral
Subject Harmine Small molecule 700 mg Oral
Subject Harmine Small molecule 900 mg Oral
Subject Harmine Small molecule 1200 mg Oral

Indications

diabetes mellitus